Morgan Stanley Upgrades Jazz Pharmaceuticals (JAZZ) to Overweight

Morgan Stanley analyst Jeffrey Hung upgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Equalweight to Overweight with a price target of $175.00 (from $140.00).

The analyst comments "Jazz hosted an investor call on Ziihera following the recent approval. With the launch of Ziihera in BTC and Phase 3 data in GEA in 2Q25, we believe the company is well-positioned for shares to appreciate in 2025. We upgrade JAZZ shares to Overweight (from Equal-weight)."

For an analyst ratings summary and ratings history on Jazz Pharmaceuticals click here. For more ratings news on Jazz Pharmaceuticals click here.

Shares of Jazz Pharmaceuticals closed at $120.72 yesterday.

You May Also Be Interested In

• Goldman Sachs Upgrades Plains GP Holdings, L.P (PAGP) to Neutral
• Medtronic, Inc. (MDT) PT Lowered to $101 at Needham
• SpaceX files for 555.56M share IPO at $135/sh